Crossmark

Treatment completion for latent tuberculosis infection in Norway: a prospective cohort study

Crossref DOI link: https://doi.org/10.1186/s12879-018-3468-z

Published Online: 2018-11-19

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Schein, Yvette Louise

Madebo, Tesfaye

Andersen, Hilde Elise

Arnesen, Trude Margrete

Dyrhol-Riise, Anne Ma

Tveiten, Hallgeir

White, Richard A.

Winje, Brita Askeland https://orcid.org/0000-0003-2858-7248
Funding

Funding for this research was provided by:

Norwegian Health Association (na)

Fullbright Scholar Program
License Information

Text and Data Mining valid from 2018-11-19
More Information

Article History

Received: 25 January 2018

Accepted: 31 October 2018

First Online: 19 November 2018

Ethics approval and consent to participate

: The study was approved by the Regional Committees for Medical and Health Research Ethics (REC South East, ref. number 2015/2122). As part of the approval exemption from consent to participate was waived based on The Health Research Act §35, §9 and §33; (i) notification of LTBI treatment in Norway is mandatory without asking for consent, (ii) treatment initiation not affected by the study, (iii) screening for TB is mandatory, which makes the monitoring and evaluation of the yield and safety of screening essential.

: Not applicable.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.